Much of this success is due to two products, Mounjaro and Zepbound, which are the same drug marketed under different brands for treating type 2 diabetes and obesity, respectively. But Mounjaro and Zepbound aren't Lilly's only drugs with blockbuster potential.

The weight-loss drugs that have become so popular in recent years actually began as diabetes medications, and a new study shows that they continue to provide strong protection against that chronic disease.

Eli Lilly's weight loss drugs are bringing in billions of dollars in revenue, and their performance even prompted the company to increase its annual revenue guidance. But one thing has limited the revenue potential of these drugs.

The weight management drug Zepbound will now be sold in lower-cost vials in addition to preloaded injector pens, according to manufacturer Eli Lilly. Here's what you need to know about how much the new drug costs,